LifeVantage reported declines in revenue and earnings for the fourth quarter and full fiscal year 2026.
For the quarter ended 30 June 2026, revenue was $42.4 million, down 23.1% year over year; net income per diluted share was $0.10 and adjusted earnings per diluted share were $0.11. Adjusted EBITDA for the quarter was $2.7 million.
The company reported regional revenue declines of 24.8% in the Americas and 16.9% in Asia/Pacific and Europe, attributing the decreases to lower order volume, smaller average order size, and reduced sales of the MindBody GLP-1 System, partially offset by October 2025 sales from its LoveBiome acquisition.
For fiscal 2026, revenue totaled $182.6 million, down 20.1% from the prior year; net income per diluted share was $0.40 and adjusted earnings per diluted share were $0.56, with adjusted EBITDA of $13.7 million.
LifeVantage reported lower gross margin percentages driven by product mix shifts and inventory obsolescence related to the MindBody GLP-1 System.
Cash from operations was $10.2 million, cash and equivalents were $14.9 million with no debt outstanding, and the firm repurchased about 336,000 shares for approximately $2.0 million, leaving $58.5 million available under a $60 million buyback program.
Due to a recent transition in the chief executive officer role, the company is not issuing formal fiscal 2027 guidance at this time.
